Gefitinib-induced pyogenic granuloma in a patient with lung cancer

Sir, Gefitinib, a tyrosine kinase inhibitor (TKI), is commonly used as first-line targeted therapy in adenocarcinoma of the lung with epidermal growth factor receptor (EGFR) exon 19 and 21 mutation. [1] Gefitinib binds to the adenosine triphosphate-binding site of the EGFR tyrosine kinase enzyme, thereby inhibiting the activation of antiapoptotic signal transduction cascade, and results in uncontrolled cell proliferation. [...]the use of gefitinib has been increased in India, and physicians used to encounter such side effect frequently in patients receiving gefitinib.